Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.

@article{Hepp2017ComparisonOA,
  title={Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.},
  author={J. Hepp and Alexander Link and Ulrike Fiedler and C. Reichen and C. Metz and Alexander Titz and Ivana Tosevski and Laurent Juglair and Patricia Schildknecht and Yvonne Kaufmann and S. Fontaine and R. Bessey and Z. Arany and C. Zitt and K. M. Dawson and Daniel Steiner and Dan Snell and V. Levitsky and Michael T. Stumpp},
  journal={Journal of Clinical Oncology},
  year={2017},
  volume={35}
}
  • J. Hepp, Alexander Link, +16 authors Michael T. Stumpp
  • Published 2017
  • Medicine
  • Journal of Clinical Oncology
  • e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to activation of T-cells. Urelumab is currently in Phase 2 clinical development and has been reported to cause significant hepatotoxicities (around 15% Grade ≥2 ALT and AST elevation) when given as infusion every 3 weeks at doses ≥0.3 mg/kg. Currently ongoing clinical trials report decreased systemic toxicity but limited efficacy at lower doses of urelumab. We… CONTINUE READING
    1 Citations
    Bispecific antibodies in cancer immunotherapy
    • 33
    • PDF